1590 completed, 525 terminated, 412 recruiting, 332 unknown. 1402 Phase 2, 1257 Phase 1, 362 Not applicable, 199 Phase 3, 58 Early Phase 1.
Follow Melanoma: new trials by email Literature Review of Melanoma trials Research Report on Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma | Not applicable | Not yet recruiting | University of Nebraska | 282 | 2026-12-24 | 2026-10-09 |
| Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 8 | 2026-12-23 | 2026-06-05 |
| Biomechanical Characterization of Skin Properties Using Impact Based-Analysis Method (IBAM) Melanoma (Skin Cancer), Skin Carcinoma | Not yet recruiting | Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris | 10 | 2026-12-03 | 2026-10-06 | |
| Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy Structured Resistance Exercise, Individualized Nutritional Support - Melanoma | Not applicable | Not yet recruiting | Institute of Oncology Ljubljana | 40 | 2026-12-01 | 2026-10-07 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Fianlimab, Cemiplimab - Melanoma (Skin) | Phase 2 | Not yet recruiting | University of California, Irvine | 35 | 2026-12-01 | 2026-09-11 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial Internet-Based Intervention, Interview, Questionnaire Administration - Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm | Not applicable | Not yet recruiting | University of Michigan Rogel Cancer Center | 142 | 2026-12-01 | 2026-10-15 |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
Showing 20 of 3373. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (410) · Neoplasms (315) · Carcinoma, Renal Cell (297) · Breast Neoplasms (290) · Neoplasm Metastasis (289) · Uveal Melanoma (279) · Colorectal Neoplasms (224) · Skin Neoplasms (210) · Lung Neoplasms (209) · Ovarian Neoplasms (190) · Sarcoma (173) · Squamous Cell Carcinoma of Head and Neck (168) · Pancreatic Neoplasms (156) · Head and Neck Neoplasms (143)
Neoplasms, Nerve Tissue (3372) · Neuroectodermal Tumors (3372) · Nevi and Melanomas (3368) · Neoplasms by Histologic Type (3364) · Neoplasms, Germ Cell and Embryonal (3362) · Neuroendocrine Tumors (3360) · Neoplasms by Site (3355) · Skin and Connective Tissue Diseases (3216) · Skin Diseases (3204) · Neoplasms (3058) · Skin Neoplasms (3001) · Neoplasms, Glandular and Epithelial (647) · Urogenital Diseases (582) · Respiratory Tract Diseases (578) · Thoracic Neoplasms (578)
pembrolizumab (310) · Nivolumab (291) · Ipilimumab (268) · Cyclophosphamide (142) · aldesleukin (141) · Interleukin-2 (109) · trametinib (85) · Dacarbazine (81) · Temozolomide (80) · dabrafenib (77) · Vemurafenib (71) · fludarabine (69) · fludarabine phosphate (63) · Biopsy (53) · binimetinib (48)
National Cancer Institute (NCI) (215) · M.D. Anderson Cancer Center (104) · Bristol-Myers Squibb (90) · Memorial Sloan Kettering Cancer Center (67) · Novartis Pharmaceuticals (47) · Hoffmann-La Roche (45) · Mayo Clinic (42) · H. Lee Moffitt Cancer Center and Research Institute (41) · Pfizer (38) · Merck Sharp & Dohme LLC (35) · GlaxoSmithKline (28) · Peking University Cancer Hospital & Institute (25) · Dana-Farber Cancer Institute (24) · University Health Network, Toronto (20) · Craig L Slingluff, Jr (19)
United States (2074) · France (368) · Australia (286) · Germany (285) · Spain (282) · United Kingdom (272) · Italy (266) · Canada (240) · Netherlands (178) · Belgium (158) · China (157) · Switzerland (150) · Poland (110) · Israel (108) · Sweden (95)
Steven A Rosenberg, M.D. (29) · Steven A. Rosenberg, MD, PhD (27) · F. Stephen Hodi, MD (14) · Paul Chapman, MD (10) · Craig L Slingluff, MD (9) · Craig L. Slingluff, MD (9)
PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 32746839, PMID 23457002, PMID 23861247, PMID 24408395, PMID 24577748, PMID 27864013, PMID 30202085, PMID 30736858, PMID 31401903, PMID 32305010, PMID 32747469, PMID 33360855, PMID 34225229, PMID 34754076, PMID 36653848, PMID 39462179, PMID 40721981, PMID 41811823, PMID 20856802, PMID 21600759, PMID 21639810, PMID 23054107, PMID 23295794, PMID 23504141, PMID 24145345, PMID 24418949, PMID 24695685, PMID 25432172, PMID 25837513, PMID 26902923, PMID 28592387, PMID 28662232, PMID 29528792, PMID 29896663, PMID 31166680, PMID 31406564, PMID 31864178, PMID 32303612, PMID 32350119, PMID 32596742, PMID 33476492
2023 (39), 2019 (27), 2016 (23), 2018 (23), 2015 (16), 2014 (15), P30CA015083 (13), 2025 (12), P30CA072720 (12), U10CA032102 (12), 2009 (11), U10CA180820 (11), 2008 (10), P30CA016672 (10), P30CA008748 (9)